Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tralokinumab in OCS-dependent asthma
NCT02281357Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Feb 2015
- Primary completion
- Sep 2017
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in asthma comparing Tralokinumab with Placebo (2 arms). Primary endpoint: Percent Change From Baseline in the Final Daily, Average, OCS Dose at Week 40 While Not Losing Asthma Control. Started Feb 2015; status: completed.
02
Drugs
tralokinumab
03
Conditions
asthma
Beyond the preview
Go deeper on NCT02281357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02281357.